skip to Main Content

Huffington Post Canada interviews Raphael Hofstein about Canadian venture capital shortage

Raphael Hofstein
Raphael Hofstein, president and CEO of MaRS Innovation

Raphael Hofstein, president and CEO of MaRS Innovation, was interviewed by Huffington Post Canada business reporter Rachel Mendleson for an article about Canada’s innovation gap and the shortage of Canadian venture capital:

One of the best ways to [raise venture capital], said Raphael Hofstein, President and CEO of Toronto-based MaRS Innovation, is to increase government investment, a lesson he learned while helping to create a life sciences early-stage fund in Israel several years ago.

“Everybody told us — institutions, industry — that they will not participate unless government has a piece of the pie. So governments have to participate, certainly in the early stage,” he said.

Continue Reading

VP Joel Liederman: MaRS Innovation, Canadian Research and the Commercialization Test

Joel Liederman, vice-president of business development and physical sciences
Joel Liederman, MI’s vice-president of business development and physical sciences

Joel Liederman, MaRS Innovation’s vice-president of Business Development and Physical Sciences, was quoted in a National Post article, published August 13, probing whether Canadian research is passing the commercialization test.

Here’s an excerpt:

While academics have often been accused of being disconnected from the real world and consuming themselves with the theoretical, it’s hard to imagine they would be able to get away with squandering funding dollars on things that make them go hmmm, particularly in light of the hyper focus on fiscal prudence.

Indeed, those who are intimately involved in attempting to bridge the commercialization gap agree that the old system of leaving university professors to their own devices had long ago been shelved in favour of a more judicious approach.

Joel Liederman, vice president of Business Development and Physical Sciences at MaRS Innovation, says there’s no doubt that much of the R&D being performed in Canada never makes it past the patent stage, but not because its origins were founded on theory instead of commercial need.

Continue Reading

Los Angeles Times covers Dr. Gregory Czarnota’s cancer therapy technology

The Los Angeles Times featured Dr. Gregory Czarnota’s research in their Science Now section on July 10, 2012, which reports on discoveries from the world of science and medicine (update: the article is no longer available online).

Czarnota, a researcher at the Sunnybrook Health Sciences Centre, is working with MaRS Innovation to license his patented technology: radiosensitization of tumour cells using a combination of microbubbles and targeted, high-intensity, focused ultrasound.

Continue Reading

Vice-President Joel Liederman to participate in Financial Post’s live chat on Canadian commercialization challenges

Joel Liederman
Joel Liederman, vice-president of Business Development and Physical Sciences at MaRS Innovation

Joel Liederman, MaRS Innovation’s vice-president of Business Development and Physical Sciences, is participating in a live chat on the Financial Post‘s website.

The chat will take place on June 28, 2012 at 2 pm.

Topic: Why Canada can’t do anything with its big ideas

When it comes to academic research and the development or discovery of new concepts or product models, there are few countries in the world that can hold a candle to Canada.

Continue Reading

Flybits featured as Canadian tech export in UKTI Youtube video

U.K. Trade and Investment (UKTI) has posted a Youtube video featuring Canadian companies looking to expand their operations to Britain.

Flybits, a Mars Innovation spin-off company, was among three companies to be profiled:

http://www.youtube.com/watch?v=9VrtJuSkYqY

Flybits is launching a corporate presence in East London’s Tech City, which is also known as the Silicon Roundabout.

Continue Reading

Montreal’s La Presse covers life science research funding project among MI, CQDM, OCE and OBI

This week, MaRS Innovation (MI) announced a new partnership agreement with The Québec Consortium for Drug Discovery (CQDM), the Ontario Brain Institute (OBI) and Ontario Centres of Excellence (OCE) to launch the Québec/Ontario CQDM Funding Program.

The funding program will support collaborative life science research projects between the two provinces that seek to develop new tools for biopharmaceutical research.

Continue Reading
Back To Top